Edge Therapeutics, Inc. (EDGE) Insider Brian A. Leuthner Sells 7,500 Shares of Stock
Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Brian A. Leuthner sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $10.53, for a total transaction of $78,975.00. Following the sale, the insider now directly owns 125,236 shares in the company, valued at $1,318,735.08. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Edge Therapeutics, Inc. (EDGE) traded up 0.77% on Friday, hitting $10.44. 20,971 shares of the company were exchanged. The company’s market capitalization is $321.85 million. The stock has a 50 day moving average of $10.30 and a 200 day moving average of $9.79. Edge Therapeutics, Inc. has a 52 week low of $7.30 and a 52 week high of $13.50.
Edge Therapeutics (NASDAQ:EDGE) last announced its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, hitting analysts’ consensus estimates of ($0.44). Analysts predict that Edge Therapeutics, Inc. will post ($1.87) EPS for the current fiscal year.
EDGE has been the topic of a number of research reports. BidaskClub raised shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research downgraded shares of Edge Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday.
A number of hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its stake in shares of Edge Therapeutics by 6.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 74,747 shares of the biotechnology company’s stock worth $681,000 after buying an additional 4,788 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Edge Therapeutics during the first quarter valued at approximately $297,000. Geode Capital Management LLC raised its position in shares of Edge Therapeutics by 5.0% in the first quarter. Geode Capital Management LLC now owns 172,646 shares of the biotechnology company’s stock valued at $1,572,000 after buying an additional 8,181 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Edge Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after buying an additional 19,973 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of Edge Therapeutics during the first quarter valued at approximately $157,000. 48.72% of the stock is owned by institutional investors.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.